• 8:30 - 18:00 M-T / 8.30 - 15.00 F

HC016 Acute Spinal Cord Injury

The HC016 platform is a treatment of acute spinal cord injury in the initial stage of the lesion, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with Histocell's proprietary technology.

Co-development agreement with:




HC016 cells modulate the inflammatory process by releasing specific enzymes and growth factors.

Additionally, cells show increased survival rates following implant due to an enhanced resistance against the cytotoxic environment in the injury site.

Development stage

Clinical Phase I/II ongoing.

Phase I completed: 8 patients with acute traumatic spinal cord injury included in 2 sequential cohorts.

Phase IIa ongoing: Randomised, controlled, double-blind. 40 patients with acute traumatic spinal cord injury divided into two groups (control and treated).


Histocell, S.L.
Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900

Our mission

We develop new healthcare products and cell therapy drugs to improve people's quality of life.

Copyright © Histocell